The invention relates to new drugs for augmenting perfusion pressure administered during cardiopulmonary resuscitation and other shock states. The compounds include phenylethanolamines and imidazolines, and fluorinated derivatives thereof, which act on adrenergic receptors in patients. The compounds of the invention enhance neurologic outcome and survival, and decrease ventricular dysrhythmias in patients suffering cardiac arrest and other shock states, relative to the outcomes, survival, and post defibrillation ventricular dysrhythmias in conventional therapy for use in resuscitation.
本发明涉及用于心肺复苏和其他休克状态下增加灌注压的新药物。该化合物包括
苯乙醇胺和
咪唑啉及其
氟化衍
生物,它们作用于患者的
肾上腺素能受体。本发明的化合物可以增强患者的神经系统预后和生存率,并减少心室心律失常,相对于常规治疗中的除颤后预后、生存率和心室心律失常,适用于复苏。